XNASOMIC
Market cap48mUSD
Dec 24, Last price
19.35USD
1D
0.47%
1Q
22.78%
IPO
-28.33%
Name
Singular Genomics Systems Inc
Chart & Performance
P/E
—
P/S
16.70
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
3m
+280.52%
Net income
-95m
L+7.42%
CFO
-74m
L-15.44%
Earnings
May 28, 2025
Profile
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 2,911 280.52% | 765 | |||
Cost of revenue | 51,233 | 46,988 | 33,788 | ||
Unusual Expense (Income) | |||||
NOPBT | (48,322) | (46,223) | (33,788) | ||
NOPBT Margin | |||||
Operating Taxes | (2,608) | 118 | |||
Tax Rate | |||||
NOPAT | (48,322) | (43,615) | (33,906) | ||
Net income | (94,820) 7.42% | (88,271) -10.74% | (98,889) 245.01% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (19) | 901 | 244,353 | ||
BB yield | 1.70% | -18.90% | -875.42% | ||
| Debt | |||||
Debt current | 15,528 | 6,323 | |||
Long-term debt | 133,911 | 101,300 | 9,904 | ||
Deferred revenue | 100 | ||||
Other long-term liabilities | 650 | (12,237) | 2,827 | ||
Net debt | (25,102) | (138,664) | (330,006) | ||
| Cash flow | |||||
Cash from operating activities | (73,647) | (87,094) | (51,701) | ||
CAPEX | (970) | (6,022) | (4,864) | ||
Cash from investing activities | 13,807 | (39,566) | (130,861) | ||
Cash from financing activities | 696 | 901 | 372,128 | ||
FCF | (68,986) | (107,281) | (37,610) | ||
| Balance | |||||
Cash | 173,941 | 244,576 | 339,223 | ||
Long term investments | 600 | 1,711 | 687 | ||
Excess cash | 174,395 | 246,249 | 339,910 | ||
Stockholders' equity | (337,433) | (243,605) | 203,621 | ||
Invested Capital | 603,526 | 550,633 | 145,283 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 2,427 | 2,372 | 2,415 | ||
Price | 0.46 -77.11% | 2.01 -82.61% | 11.56 | ||
Market cap | 1,116 -76.58% | 4,767 -82.92% | 27,913 | ||
EV | (23,986) | (133,897) | 53,555 | ||
EBITDA | (41,099) | (40,191) | (32,655) | ||
EV/EBITDA | 0.58 | 3.33 | |||
Interest | 1,101 | 763 | 846 | ||
Interest/NOPBT | |||||